BR112022000144A2 - Compostos que compreendem um ligante de proteína de ativação de fibroblastos e uso dos mesmos - Google Patents

Compostos que compreendem um ligante de proteína de ativação de fibroblastos e uso dos mesmos

Info

Publication number
BR112022000144A2
BR112022000144A2 BR112022000144A BR112022000144A BR112022000144A2 BR 112022000144 A2 BR112022000144 A2 BR 112022000144A2 BR 112022000144 A BR112022000144 A BR 112022000144A BR 112022000144 A BR112022000144 A BR 112022000144A BR 112022000144 A2 BR112022000144 A2 BR 112022000144A2
Authority
BR
Brazil
Prior art keywords
compounds
activating protein
protein ligand
fibroblast activating
xaa1
Prior art date
Application number
BR112022000144A
Other languages
English (en)
Inventor
Aileen Höhne
Anne Bredenbeck
Christian Haase
Christiane Smerling
Dirk Zboralski
Eberhard Schneider
Frank Osterkamp
Jan Ungewiss
Matthias Paschke
Ulrich Reineke
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19000325.1A external-priority patent/EP3763726A1/en
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of BR112022000144A2 publication Critical patent/BR112022000144A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Abstract

compostos que compreendem um ligante de proteína de ativação de fibroblastos e uso dos mesmos. a presente invenção refere-se a um composto que compreende um peptídeo cíclico de fórmula (i) e um grupo a de modificação n-terminal ligado a xaa1, em que cada um e qualquer um dentre xaa1, xaa2, xaa3, xaa4, xaa5, xaa6 e xaa7 é um resíduo de aminoácido, e yc é uma estrutura de fórmula (x).
BR112022000144A 2019-07-08 2020-07-08 Compostos que compreendem um ligante de proteína de ativação de fibroblastos e uso dos mesmos BR112022000144A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19000325.1A EP3763726A1 (en) 2019-07-08 2019-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof
EP19198810 2019-09-20
PCT/EP2020/069308 WO2021005131A1 (en) 2019-07-08 2020-07-08 Compounds comprising a fibroblast activation protein ligand and use thereof

Publications (1)

Publication Number Publication Date
BR112022000144A2 true BR112022000144A2 (pt) 2022-02-22

Family

ID=71409440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000144A BR112022000144A2 (pt) 2019-07-08 2020-07-08 Compostos que compreendem um ligante de proteína de ativação de fibroblastos e uso dos mesmos

Country Status (12)

Country Link
US (1) US20220315554A1 (pt)
EP (1) EP3997104A1 (pt)
JP (1) JP2022541752A (pt)
KR (1) KR20220032078A (pt)
CN (1) CN114341158A (pt)
AU (1) AU2020309161A1 (pt)
BR (1) BR112022000144A2 (pt)
CA (1) CA3145872A1 (pt)
CL (1) CL2022000016A1 (pt)
IL (1) IL289673A (pt)
MX (1) MX2022000251A (pt)
WO (1) WO2021005131A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115943312A (zh) 2020-05-07 2023-04-07 法国居里学院 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
TW202340226A (zh) * 2021-12-17 2023-10-16 德商３Ｂ製藥有限公司 碳酸酐酶ix配位體
WO2023152671A1 (en) 2022-02-09 2023-08-17 Novartis Ag Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
CN1163594C (zh) 1997-09-29 2004-08-25 尖端医疗有限公司 体外造血细胞的刺激
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7374898B2 (en) 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
AU2006246719A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
US8933201B2 (en) 2006-06-07 2015-01-13 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use
JP2010523477A (ja) 2007-03-20 2010-07-15 トラスティーズ オブ タフツ カレッジ 線維芽細胞活性化タンパク質の阻害剤、およびそれを使用する方法
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
RU2011116223A (ru) 2008-09-25 2012-10-27 Моликьюлар Инсайт Фармасьютикалз, Инк. (Us) Селективные ингибиторы сепразы
AU2010301105A1 (en) 2009-10-02 2012-04-19 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
PT2603530T (pt) 2010-08-13 2018-01-09 Roche Glycart Ag Anticorpos anti-fap e métodos de utilização
WO2013107820A1 (en) 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
KR102263685B1 (ko) * 2012-03-21 2021-06-11 다케다 야쿠힌 고교 가부시키가이샤 Tfpi 저해제 및 사용 방법
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
WO2015188934A1 (en) * 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2017127007A1 (en) * 2016-01-20 2017-07-27 Poypeptide Laboratories Holding (Ppl) Ab METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
KR20190016544A (ko) 2016-06-10 2019-02-18 바이엘 파마 악티엔게젤샤프트 방사성-제약 복합체
CN105949282B (zh) * 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v2及其应用
CN106046121B (zh) * 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v1及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3088138A1 (en) 2017-10-23 2019-05-02 The Johns Hopkins University Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha)

Also Published As

Publication number Publication date
CA3145872A1 (en) 2021-01-14
IL289673A (en) 2022-03-01
EP3997104A1 (en) 2022-05-18
WO2021005131A1 (en) 2021-01-14
CN114341158A (zh) 2022-04-12
MX2022000251A (es) 2022-02-21
KR20220032078A (ko) 2022-03-15
US20220315554A1 (en) 2022-10-06
CL2022000016A1 (es) 2022-08-19
JP2022541752A (ja) 2022-09-27
AU2020309161A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
BR112022000144A2 (pt) Compostos que compreendem um ligante de proteína de ativação de fibroblastos e uso dos mesmos
BR112022000122A2 (pt) Compostos que compreendem um ligante de proteína de ativação de fibroblasto e uso dos mesmos
MX364911B (es) Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial.
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
UA103015C2 (ru) Новые производные инсулина с чрезвычайно замедленным профилем время/действие
CL2012001230A1 (es) Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c.
CL2023001991A1 (es) Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo
MY152979A (en) Novel insulin derivatives having an extremely delayed time-action profile
MX2021002569A (es) Composiciones y metodos para el tratamiento de infecciones virales.
PE20091753A1 (es) Conjugados antagonistas peptidicos analogos a la bombesina
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
NZ598579A (en) Oxytocin receptor agonists
NZ610732A (en) Novel angiotensin type 2 (at2) receptor agonists and uses thereof
MX2022002728A (es) Composiciones y metodos para el tratamiento de infecciones virales.
WO2019014260A3 (en) BLOOD COMPONENT POTENTIATION OF ANTIBACTERIAL ACTIVITY OF THE LYTIC PROTEIN AND METHODS AND USES THEREOF
RU2015146739A (ru) Комплексы типа сахаридная цепочка-полипептид
DK1691827T3 (da) Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock
CA2863661C (en) Diagnostic peptides for lyme disease
MX2020006601A (es) Composicion inmunogenica.
MY160435A (en) A novel antiviral peptide against avian influenza virus h9n2
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
BR112015031679A2 (pt) conjugado de peptídeo-resina e seu uso
RU2015130287A (ru) Адаптация вируса гриппа н5 к человеку
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
ES2607490T3 (es) Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen